ApaTech(R) Launches the Actifuse(R) MIS Bone Graft Delivery System: Reaching New Levels in Synthetic Bone Grafting
Growth of Minimally Invasive Surgery (MIS) and surgeon demand for devices to precisely deliver graft material to the surgical site has led to the development of the Actifuse(R) MIS System. Actifuse MIS provides extended reach, controlled delivery and precise placement for surgeons performing open and minimally invasive procedures and who require a synthetic bone graft substitute. The product is ready for immediate, off the shelf use.
The Actifuse(R) MIS System is ideal for use in a range of spinal and orthopedic procedures including posterolateral fusion, bone void filling and acetabular cysts. The applicator facilitates controlled bone graft delivery through 200mm x 8mm pre-filled devices with replacement cartridges available for additional volume requirements.
The Actifuse(R) MIS System contains Actifuse(R) ABX, a unique osteostimulative bone graft characterized by:
- Acceleration of bone formation. - Physiologically mediated resorption. - Demonstrated clinical success.
Actifuse ABX contains 96% granules and can be placed directly into the operative site with no need to mix with blood or bone marrow aspirate. The silicate substituted calcium phosphate chemistry of Actifuse offers a significant advance in synthetic bone graft technology.
Commenting on the launch of the Actifuse(R) MIS System, ApaTech CEO
Notes to Editors:
ApaTech specializes in producing synthetic bone repair material. It has
The Company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse(R), which underpins the Company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth.
ApaTech is backed by international investors, Encore Ventures and
Healthcor and following its formation in 2001, the Company has raised more
ApaTech is committed to delivering shareholder value by using its scientific leadership to provide targeted solutions to physicians, allowing them to significantly improve patient outcomes.
ApaTech has received several corporate business and research awards,
including the Frost & Sullivan '2009 North American Biologics Company of the
Year' as a result of its success in the US orthobiologics market. More
recently, ApaTech was awarded 3rd place in the UK Deloitte Technology Fast 50
(2009), in addition to being recognized as
More details can be found at http://www.apatech.com
The unique silicate substituted calcium phosphate chemistry of Actifuse is a significant advance in synthetic bone graft technology and provides surgeons with a safe and effective alternative to both autograft and allograft. Actifuse stimulates the formation of bone and improves the subsequent organization and strength of the graft/host bone composite structure. Unlike traditional calcium phosphate based products, Actifuse is steadily and predictably remodeled by the host biology over time, ensuring that sufficient conductive scaffold remains for the duration of new bone growth and its subsequent maturation.
Actifuse is available as a range of granule and microgranule formulations which include Actifuse E-Z Prep delivered in a granule applicator. Actifuse is also available as an Advanced Bone matriX; Actifuse ABX, in a standard applicator and now in a purpose designed minimally invasive applicator, the Actifuse MIS System.
Actifuse family of bone graft substitutes are CE marked and U.S. FDA 510(k) cleared for use as a bone void filler intended only for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. Actifuse is indicated to be packed gently into bony voids or gaps of the skeletal system, i.e., extremities, pelvis, and spine, including use in posterolateral fusion procedures with appropriate stabilizing hardware. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by bone during the healing process.
Further Information: ApaTech Simon Cartmell, CEO, +44-(0)-20-8731-4640 Simon.email@example.com Waughton Robin Hepburn, +44-(0)-20-7796-9999 firstname.lastname@example.org